Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Atai Life Sciences N.V. (NQ: ATAI )

1.080 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atai Life Sciences N.V.

< Previous 1 2
...
20 21 22 23 24 25 26 27 Next >
Psychedelic Stock Gainers And Losers From January 18, 2022
GAINERS: Cybin (AMEX: 
Via Benzinga
Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS
New Awakn Study Shows Ketamine Has Potential To Treat Alcoholism Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: 
Via Benzinga
The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Biogen Shares Slip On Restricted Coverage For Its Alzheimer's Drug Biogen... 
Via Benzinga
A Recap of How Psychedelics Fared in 2021
Via Investor Brand Network
Why Jim Cramer Likes Illumina And Enterprise Products Partners
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Illumina, Inc. (NASDAQ: 
Via Benzinga
Year-End Summary: Marijuana & Psychedelic Compounds-Based Drug Stocks Index Went DOWN -33.6% In 2021!
Which index performed the best in 2021, the Marijuana Drug Stocks Index, or the Psychedelic Compounds-Based Drug Stocks Index? Which constituents contributed to their performances? This article has the... 
Via Talk Markets
2021 Was The Year Psychedelics Conquered Capitalism...Or Is It The Other Way Around?
Witnessing an entirely new industry being created from scratch is a rare and historic event, one that brings with it tremendous opportunity for inv... 
Via Benzinga
Steep Decline In Cannabis & Psychedelic Compounds-Based Drug Stocks Continues: DOWN -16.6% MTD
All 12 constituents in the Marijuana & Psychedelic Compounds-Based Drug Stocks Index continue to decline. How do their performances compare month-to-date and YTD? 
Via Talk Markets
The Year In Review For Psychedelic Drug Stocks: 2021
2021 was two different 
Via Talk Markets
Mobile Clinics Featuring Novel Mental Health Treatments Reportedly Coming to Florida and Nevada
Photo by Insung Yoon on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
46 Biggest Movers From Yesterday
Gainers Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) gained 34.1% to settle at $12.58 on Wednesday. CMC Materials, Inc. (NASDAQ: CCMP) climbed 33.9% to close at $195.50 on... 
Via Benzinga
36 Stocks Moving In Wednesday's Mid-Day Session
Gainers Nxt-ID, Inc. (NASDAQ: NXTD) shares gained 28.9% to $3.21 after the company said it was awarded U.S. General Services Administration contract to distribute personal... 
Via Benzinga
Dow Down Triple Digits as Fed Meeting Wraps Up
Stocks have deepened their morning losses by midday, with the Dow Jones Industrial Average down 119 points, while both the Nasdaq Composite and S&P 500 Index are firmly in the red as well. 
Via Talk Markets
Mid-Morning Market Update: Markets Open Lower; US Retail Sales Miss Estimates
Following the market opening Wednesday, the Dow traded down 0.26% to 35,453.17 while the NASDAQ fell 0.62% to 15,142.70. The S&P also fell, dropping 0.28% to 4,621.34. The U.S... 
Via Benzinga
North American Psychedelic Drugs Market Expected To Reach A Value Of $3.184 Billion In 2026
Palm Beach, FL –December 14, 2021 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially, and the development of novel medications has not kept... 
Via FinancialNewsMedia
Entheon Biomedical Reports Launching Multiple Studies to Advance Psychedelic-Based Mental Health Treatments
Image provided by Flickr The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
Via Benzinga
Trip to Sustainability? This Company Is Developing Synthetic Psychedelics To Attempt to Fight Mental Illness
Photo by Raimond Klavins 
Via Benzinga
Cannabis & Psychedelic Compound-Based Drug Stocks Continue To Decline
The six marijuana-based clinical-stage stocks are down 31.1% since the end of June; the 9 psychedelic compound-based clinical-stage stocks with market caps under $1B are down 36.3% in that same... 
Via Talk Markets
Topics Cannabis
Exposures Cannabis
Psilera's DMT-Derived Drug Sees Positive Results in Pre-Clinical Study
Psilera is a Florida-based biotechnology company focused on developing drugs to treat mental disorders using non-hallucinogenic derivatives from psychedelic compounds. The... 
Via Benzinga
Topics Derivatives
Exposures Derivatives
National Institute on Drug Abuse Will Test Ibogaine For Addiction Treatment As Drug Deaths Crest 100,000
The U.S. government has taken a significant step toward tackling the mounting national substance addiction crisis by partnering with neuroscience company Delix Therapeutics... 
Via Benzinga
Topics Death
Exposures Death
This Company Is Making Synthetic Psychedelics With a Goal To Combat Mental Illness
Photo by Michael Longmire on... 
Via Benzinga
Atai Life Sciences (NASDAQ: ATAI) Increases Stake in Psychedelic Start-Up Compass Pathways
Via Investor Brand Network
New York's Horizons Psychedelic Conference Highlights Big Donations In The Growing Industry
Venture capitalist and businessman Stephen Jurvetson is joining an expanding group of prominent invest... 
Via Benzinga
Both Marijuana & Psychedelic Compounds-Based Drug Stocks Indexes Declined Sharply In November
A look at which critical stage drug stock category performed best in November and which constituents contributed to that performance. 
Via Talk Markets
Topics Cannabis
Exposures Cannabis
Analyst Ratings For ATAI Life Sciences
Over the past 3 months, 6 analysts have published their opinion on ATAI Life Sciences (NASDAQ: 
Via Benzinga
Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass Pathways
Biopharmaceutical conglomerate ATAI Life Sciences (NASDAQ:ATAI), a ... 
Via Benzinga
Psychedelic Drug Stocks Continued To Decline Last Week
The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021
Upgrades Sidoti & Co. upgraded the previous rating for DMC Global Inc (NASDAQ: 
Via Benzinga
Use of Ketamine for Mental Disorders Rising While New Therapies Emerge
Palm Beach, FL –November 17, 2021 – FinancialNewsMedia.com News Commentary – The uses of Ketamine for a variety of therapies are growing. An expanding number of clinics are offering ketamine infusion... 
Via FinancialNewsMedia
70 Biggest Movers From Yesterday
Gainers Casper Sleep Inc. (NYSE: CSPR) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be acquired by Durational Capital Management. The... 
Via Benzinga
< Previous 1 2
...
20 21 22 23 24 25 26 27 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.